

Beverly Moy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8842980/publications.pdf>

Version: 2024-02-01

166
papers

6,123
citations

109321
35
h-index

76900
74
g-index

168
all docs

168
docs citations

168
times ranked

7323
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of patient navigation programs for breast cancer patients across the city of Boston. Supportive Care in Cancer, 2022, 30, 2435-2443.	2.2	3
2	Enhancing Health Equity Through Cancer Health Economics Research. Journal of the National Cancer Institute Monographs, 2022, 2022, 74-78.	2.1	1
3	Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. Journal of Clinical Oncology, 2022, 40, 787-800.	1.6	44
4	Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 136-143.	4.9	19
5	Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care. Oncologist, 2022, 27, 518-524.	3.7	6
6	Abstract P3-13-01: Association of polygenic risk score with 2 year risk of poor prognosis breast cancer. Cancer Research, 2022, 82, P3-13-01-P3-13-01.	0.9	0
7	Abstract P3-09-11: Clinical characteristics associated with BRCA1/2 mutations identified on routine tumor tissue genotyping in metastatic breast cancer. Cancer Research, 2022, 82, P3-09-11-P3-09-11.	0.9	0
8	Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation. Cancer Research, 2022, 82, P1-18-22-P1-18-22.	0.9	0
9	Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1). Cancer Research, 2022, 82, P1-14-02-P1-14-02.	0.9	1
10	Abstract P4-12-08: Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App. Cancer Research, 2022, 82, P4-12-08-P4-12-08.	0.9	0
11	Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors. Cancer Research, 2022, 82, P3-23-02-P3-23-02.	0.9	0
12	Abstract PD5-11: Pilot study to assess prolonged nightly fasting in breast cancer survivors (LONGFAST). Cancer Research, 2022, 82, PD5-11-PD5-11.	0.9	0
13	Abstract P3-16-01: Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC). Cancer Research, 2022, 82, P3-16-01-P3-16-01.	0.9	0
14	CLO22-033: Clinicopathologic and Sociodemographic Factors Associated With Late Relapse Triple Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, CLO22-033.	4.9	0
15	Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast). Breast Cancer Research and Treatment, 2022, , .	2.5	5
16	Utilizing Natural Language Processing (NLP) to identify breast cancer associated-lung metastases from pathology reports to delineate characteristics and challenges of this common site of breast cancer recurrence.. Journal of Clinical Oncology, 2022, 40, e13592-e13592.	1.6	0
17	Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.. Journal of Clinical Oncology, 2022, 40, 512-512.	1.6	22
18	Financial Toxicity, Symptom Burden, Illness Perceptions, and Communication Confidence in Cancer Clinical Trial Participants. JCO Oncology Practice, 2022, 18, e1427-e1437.	2.9	4

#	ARTICLE	IF	CITATIONS
19	Adjuvant trastuzumab and vinorelbine (TV) for early-stage HER2+ breast cancer.. Journal of Clinical Oncology, 2022, 40, e12521-e12521.	1.6	0
20	Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2022, 40, 3205-3221.	1.6	43
21	Baseline preferences for digital information engagement in patients with breast cancer by age and status of diagnosis.. Journal of Clinical Oncology, 2022, 40, e24119-e24119.	1.6	0
22	Implementation of a Brief Screening Tool to Identify Needs of Breast Cancer Survivors. Clinical Breast Cancer, 2021, 21, e88-e95.	2.4	4
23	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical Breast Cancer, 2021, 21, 80-91.e7.	2.4	140
24	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3404-3413.	7.0	10
25	Abstract PS18-19: Comparison of metastatic genomic profile in patients <45 years and patients >45 years with triple-negative breast cancer. , 2021, , .		0
26	Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and <2 prior HER2-directed regimens. , 2021, , .		1
27	Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer. , 2021, , .		0
28	Neratinib+capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and<2 prior HER2-directed regimens. Breast Cancer Research and Treatment, 2021, 188, 449-458.	2.5	2
29	Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.. Journal of Clinical Oncology, 2021, 39, 540-540.	1.6	4
30	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 3059-3059.	1.6	0
31	Feasibility of integrating the Outcomes4Me smartphone navigation application into the care of breast cancer patients (FIONA).. Journal of Clinical Oncology, 2021, 39, 1570-1570.	1.6	1
32	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. Oncologist, 2021, 26, e1327-e1338.	3.7	31
33	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. Oncologist, 2021, 26, 827-834.	3.7	28
34	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 3938-3958.	1.6	40
35	Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 797-804.	4.9	11
36	Disparities in phase 1 cancer clinical trial enrollment. Cancer, 2021, 127, 4464-4469.	4.1	15

#	ARTICLE	IF	CITATIONS
37	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5818-5827.	7.0	14
38	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 103.	5.2	17
39	Financial toxicity, symptom burden, illness perceptions, and communication confidence in cancer clinical trial participants.. <i>Journal of Clinical Oncology</i> , 2021, 39, 86-86.	1.6	1
40	Implementing a patient navigation program to improve adherence with cancer treatment for community health center patients newly diagnosed with cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 103-103.	1.6	2
41	Illness perceptions, financial toxicity, symptom burden, and survival in cancer clinical trial (CCT) participants.. <i>Journal of Clinical Oncology</i> , 2021, 39, 160-160.	1.6	0
42	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-8.	4.9	36
43	Antibody drug conjugates for patients with breast cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100795.	2.0	3
44	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	2.4	21
45	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1246-1262.	3.0	16
46	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With 2 HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3138-3149.	1.6	355
47	A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 515-524.	2.5	11
48	Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. <i>Radiation Oncology</i> , 2020, 15, 198.	2.7	4
49	The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. <i>Journal of Oncology Pharmacy Practice</i> , 2020, , 107815522097175.	0.9	2
50	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	30.7	83
51	Identification of Somatically Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	7.0	12
52	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. <i>Lancet, The</i> , 2020, 395, 817-827.	13.7	260
53	Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020, 383, 262-272.	27.0	12
54	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2838-2848.	7.0	403

#	ARTICLE	IF	CITATIONS
55	Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. <i>BMC Cancer</i> , 2020, 20, 347.	2.6	10
56	Randomized trial of a collaborative palliative and oncology care intervention to improve communication about end-of-life care in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1008-1008.	1.6	4
57	Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1066-1066.	1.6	13
58	Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1094-1094.	1.6	1
59	Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER).. <i>Journal of Clinical Oncology</i> , 2020, 38, 531-531.	1.6	3
60	Medical oncologists'™ perceptions of clinical trials for underrepresented populations.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19062-e19062.	1.6	0
61	Factors associated with frequent insomnia among breast cancer survivors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24098-e24098.	1.6	0
62	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2529-2529.	1.6	0
63	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , 2020, 22, ii147-ii147.	1.2	0
64	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 18.	5.4	25
65	Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients. <i>Medical Decision Making</i> , 2019, 39, 642-650.	2.4	10
66	Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study. <i>Cancer</i> , 2019, 125, 4532-4540.	4.1	11
67	Local"regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	2.5	30
68	Expanding Access to Cancer Clinical Trials for Patients With Mental Illness. <i>Journal of Clinical Oncology</i> , 2019, 37, 1524-1528.	1.6	10
69	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	5.0	17
70	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2"Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	1.6	229
71	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2"Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	1.6	251
72	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with "2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1002-1002.	1.6	71

#	ARTICLE	IF	CITATIONS
73	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.. Journal of Clinical Oncology, 2019, 37, 1028-1028.	1.6	5
74	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1057-1057.	1.6	27
75	Implementation of a brief screening tool to identify needs of cancer survivors.. Journal of Clinical Oncology, 2019, 37, e23075-e23075.	1.6	1
76	Working together in cancer care: An academic community partnership for a diverse patient population.. Journal of Clinical Oncology, 2019, 37, 10525-10525.	1.6	0
77	AR Expression in Breast Cancer CTCs Associates with Bone Metastases. Molecular Cancer Research, 2018, 16, 720-727.	3.4	68
78	Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. Journal of Clinical Oncology, 2018, 36, 3331-3339.	1.6	58
79	NIMG-63. ADVANCED IMAGING FOR ASSESSING VOLUMETRIC RESPONSES IN BRAIN METASTASES TREATED WITH CHECKPOINT BLOCKADE. Neuro-Oncology, 2018, 20, vi190-vi190.	1.2	0
80	Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Research and Treatment, 2018, 172, 733-740.	2.5	15
81	Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer.. Journal of Clinical Oncology, 2018, 36, 576-576.	1.6	2
82	Addressing financial concerns of cancer clinical trial participants: Longitudinal outcomes of an equity intervention.. Journal of Clinical Oncology, 2018, 36, 6566-6566.	1.6	0
83	Considering cost and value with patients in clinic.. Journal of Clinical Oncology, 2018, 36, e18905-e18905.	1.6	0
84	Delays in initial breast cancer treatment among black and white women in Boston.. Journal of Clinical Oncology, 2018, 36, e18620-e18620.	1.6	0
85	Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.. Journal of Clinical Oncology, 2018, 36, 1021-1021.	1.6	0
86	Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, 1020-1020.	1.6	10
87	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 163, 535-544.	2.5	16
88	Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist, 2017, 22, 1039-1048.	3.7	115
89	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1688-1700.	10.7	451
90	Survivorship Model of Care: Development and Implementation of a Nurse Practitionerâ€œLed Intervention for Patients With Breast Cancer. , 2017, 21, E99-E105.		8

#	ARTICLE	IF	CITATIONS
91	Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI). Biomedical Optics Express, 2017, 8, 555.	2.9	21
92	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncologyâ€“Cancer Care Ontario Focused Guideline Update. Journal of Clinical Oncology, 2017, 35, 3978-3986.	1.6	127
93	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncologyâ€“Cancer Care Ontario Focused Guideline Update Summary. Journal of Oncology Practice, 2017, 13, 822-824.	2.5	9
94	TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).. Journal of Clinical Oncology, 2017, 35, 1005-1005.	1.6	32
95	FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer.. Journal of Clinical Oncology, 2017, 35, 1013-1013.	1.6	5
96	Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2017, 35, 1046-1046.	1.6	4
97	Impact of <i>PIK3CA</i> tumor mutation on the association of aspirin or NSAID use and time to breast cancer recurrence.. Journal of Clinical Oncology, 2017, 35, 1521-1521.	1.6	2
98	Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2017, 35, 511-511.	1.6	43
99	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.. Journal of Clinical Oncology, 2017, 35, TPS1106-TPS1106.	1.6	1
100	Breast cancer care redesign as an approach to streamline survivorship care: Outcomes and challenges.. Journal of Clinical Oncology, 2017, 35, 9-9.	1.6	0
101	Are NCI-designated cancer centers websites linguistically accessible?. Journal of Clinical Oncology, 2017, 35, e18078-e18078.	1.6	0
102	Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e22-e29.	3.8	5
103	Announcing a New Journal Section: Community Outreach. Oncologist, 2016, 21, 1-1.	3.7	41
104	Neoadjuvant Endocrine Therapy for Estrogen Receptorâ€“Positive Breast Cancer. JAMA Oncology, 2016, 2, 1477.	7.1	259
105	Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. Oncologist, 2016, 21, 467-474.	3.7	70
106	Distribution and Patterns of Industry-Related Payments to Oncologists in 2014. Journal of the National Cancer Institute, 2016, 108, djw163.	6.3	53
107	No Conflict, No Interest. JAMA Oncology, 2016, 2, 1631.	7.1	4
108	The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?. Oncologist, 2016, 21, 1411-1413.	3.7	1

#	ARTICLE	IF	CITATIONS
109	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. European Journal of Cancer, 2016, 56, 85-92.	2.8	4
110	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 367-377.	10.7	444
111	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2â€Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology, 2016, 34, 945-952.	1.6	148
112	Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Research and Treatment, 2016, 155, 569-578.	2.5	20
113	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 29.	7.1	68
114	Financial burden in adult cancer survivors: Care affordability and accessibility.. Journal of Clinical Oncology, 2016, 34, 6535-6535.	1.6	4
115	Prospective study of the financial burden of cancer clinical trial patients referred to a cancer care equity program (CCEP).. Journal of Clinical Oncology, 2016, 34, e18056-e18056.	1.6	0
116	Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 586-586.	1.6	0
117	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research, 2015, 17, 56.	5.0	30
118	The Impact of Industry on Oncology Research and Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 130-137.	3.8	14
119	Recognizing the Financial Burden of Cancer Patients in Clinical Trials. Oncologist, 2015, 20, 572-575.	3.7	43
120	Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene. Oncologist, 2015, 20, 571-571.	3.7	1
121	Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience. Journal of Clinical Oncology, 2015, 33, 340-348.	1.6	94
122	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multiâ€institutional study. Cancer, 2015, 121, 1937-1948.	4.1	8
123	Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. International Journal of Radiation Oncology Biology Physics, 2015, 93, 622-630.	0.8	77
124	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. European Journal of Cancer, 2015, 51, 685-696.	2.8	10
125	Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. Journal of Clinical Oncology, 2015, 33, 3621-3627.	1.6	172
126	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).. Journal of Clinical Oncology, 2015, 33, 508-508.	1.6	16

#	ARTICLE	IF	CITATIONS
127	Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.. Journal of Clinical Oncology, 2015, 33, 117-117.	1.6	1
128	Genomic landscape of primary breast cancer in black vs. white women and association with tumor recurrence.. Journal of Clinical Oncology, 2015, 33, 6553-6553.	1.6	1
129	Financial burden of cancer clinical trials: Impact of an equity program intervention.. Journal of Clinical Oncology, 2015, 33, 6501-6501.	1.6	0
130	Hospitalizations and emergency department use in cancer clinical trial patients.. Journal of Clinical Oncology, 2015, 33, 160-160.	1.6	1
131	Palliative care consultation for patients enrolled in cancer clinical trials.. Journal of Clinical Oncology, 2015, 33, 139-139.	1.6	2
132	American Society of Clinical Oncology Policy Statement on Medicaid Reform. Journal of Clinical Oncology, 2014, 32, 4162-4167.	1.6	36
133	Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. Oncologist, 2014, 19, 348-349.	3.7	23
134	Geriatric Oncology for the 21st Century: A Call for Action. Journal of Oncology Practice, 2014, 10, 241-243.	2.5	16
135	Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. Oncologist, 2014, 19, 346-347.	3.7	14
136	Debating the Oncologist's Role in Defining the Value of Cancer Care: Our Duty Is to Our Patients. Journal of Clinical Oncology, 2014, 32, 4039-4041.	1.6	13
137	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2â€“Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 3307-3329.	1.6	210
138	Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. Journal of Clinical Oncology, 2014, 32, 2142-2150.	1.6	207
139	Value of Cancer Care: Ethical Considerations for the Practicing Oncologist. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e146-e149.	3.8	8
140	Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC).. Journal of Clinical Oncology, 2014, 32, 522-522.	1.6	0
141	Alleviating financial burden for cancer patients in clinical trials.. Journal of Clinical Oncology, 2014, 32, 10-10.	1.6	0
142	Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. Biomedical Optics Express, 2013, 4, 2911.	2.9	32
143	Correlation Between Financial Relationships With Commercial Interests and Research Prominence at an Oncology Meeting. Journal of Clinical Oncology, 2013, 31, 2678-2684.	1.6	14
144	Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).. Journal of Clinical Oncology, 2013, 31, 1006-1006.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 630-630.	1.6	0
146	Risk perceptions in localized breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 9534-9534.	1.6	0
147	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. Journal of Clinical Oncology, 2013, 31, 533-533.	1.6	0
148	NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction.. Journal of Clinical Oncology, 2013, 31, 6557-6557.	1.6	0
149	Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 647-647.	1.6	0
150	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. Journal of Clinical Oncology, 2013, 31, 145-145.	1.6	0
151	Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer.. Journal of Clinical Oncology, 2013, 31, 147-147.	1.6	1
152	Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 167-167.	1.6	0
153	Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN).. Journal of Clinical Oncology, 2012, 30, 599-599.	1.6	2
154	Core Elements of the Patient Protection and Affordable Care Act and Their Relevance to the Delivery of High-Quality Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , e4-e8.	3.8	7
155	Association between financial relationships with commercial interests and researchÂmerit at the ASCO Annual Meeting (AM).. Journal of Clinical Oncology, 2012, 30, 6095-6095.	1.6	0
156	Financial relationships with commercial interests (COI) among abstracts at the ASCO Annual Meeting.. Journal of Clinical Oncology, 2012, 30, 6128-6128.	1.6	0
157	Lapatinib in HER2+ early breast cancer: Quality of life analysis.. Journal of Clinical Oncology, 2012, 30, 604-604.	1.6	0
158	Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.. Journal of Clinical Oncology, 2012, 30, 596-596.	1.6	0
159	Patient Navigator Programs, Cancer Disparities, and the Patient Protection and Affordable Care Act. Oncologist, 2011, 16, 926-929.	3.7	27
160	American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities. Journal of Clinical Oncology, 2011, 29, 3816-3824.	1.6	122
161	Medical Integrity Up in Smoke? Conflicts of Interest and the Lung Cancer Screening Controversy. Oncologist, 2008, 13, 474-476.	3.7	5
162	Lapatinib-Associated Toxicity and Practical Management Recommendations. Oncologist, 2007, 12, 756-765.	3.7	109

#	ARTICLE	IF	CITATIONS
163	TEACH: Tykerb Evaluation After Chemotherapy. <i>Clinical Breast Cancer</i> , 2007, 7, 489-492.	2.4	26
164	Barriers to repeat mammography: cultural perspectives of African-American, Asian, and Hispanic women. <i>Psycho-Oncology</i> , 2006, 15, 623-634.	2.3	65
165	Lapatinib: Current Status and Future Directions in Breast Cancer. <i>Oncologist</i> , 2006, 11, 1047-1057.	3.7	138
166	Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches. <i>Clinical Cancer Research</i> , 2006, 12, 4790-4793.	7.0	59